We are live on ! Find out more
KAPA

Kairos Pharma
KAPA

14 hedge funds and large institutions have $371K invested in Kairos Pharma in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

27% more funds holding

Funds holding: 11 → 14 (+3)

9% more capital invested

Capital invested by funds: $342K → $371K (+$29.6K)

0.23% more ownership

Funds ownership: 0.41% → 0.65% (+0.23%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$161K
2
VF
Virtu Financial
New York
+$42.6K
3
Jane Street
Jane Street
New York
+$17.5K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$15.2K
5
XT
XTX Topco
Cayman Islands
+$7.74K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$22.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$16.8K
3
HF
HRT Financial
New York
-$12K
4
TSS
Two Sigma Securities
New York
-$9.08K
5
TRCT
Tower Research Capital (TRC)
New York
-$120

KAPA Hedge Fund Activity: Q2 2026 in Review

14 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q2 2026, worth a combined $371K — up 8.7% from $342K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new KAPA positions and 4 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $161K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $22.1K sold.

  • 14 institutional investors held Kairos Pharma (KAPA) as of Q2 2026, up from 11 in Q1 2026.
  • Funds reported $371K of Kairos Pharma stock for Q2 2026, up 8.7% quarter-over-quarter.
  • 7 funds opened new Kairos Pharma positions in Q2 2026 and 4 closed out, a net change of +3 holders.
  • The largest Kairos Pharma buyer in Q2 2026 was Citadel Advisors, an estimated $161K added.
  • The largest Kairos Pharma seller in Q2 2026 was Two Sigma Investments, an estimated $22.1K sold.

Based on aggregated 13F filings for Q2 2026.